AMBRAmber International Holding Ltd
The schedule
- Tue15Sep
Management may pursue an equity or convertible raise in late Q3 to secure capital for the next wave of developments and reinforce liquidity after the March loss. If Amber can place a modestly sized deal with strategic investors at only a small discount and clearly earmark proceeds for high-IRR projects, shares could recover toward $1.60. A deeply dilutive raise at a steep discount or structured financing with punitive terms could instead drive the stock down toward $1.60.
- Sun15Nov
Amber’s roadmap implies at least one sizable project sale or construction milestone in late 2026. Successfully closing a sale at or above book value, or securing a binding presale on favorable terms, would validate the portfolio valuation and could lift the stock toward $1.30. If the project slips, is repriced lower, or reveals impairments, concerns about asset quality and the sustainability of earnings could pull the shares down toward $1.30.
- Thu4Mar
The Q3 2026 earnings release, likely in late November, will show whether Amber has converted its project pipeline into stabilized revenue and narrowed losses after any mid-year financing or asset sales. A quarter with improving margins, clear visibility into future presales, and disciplined use of capital could support a rebound toward $0.60. Continued losses or new impairments would reinforce the distressed narrative and keep the stock anchored closer to $0.30.
- Thu3Jun
- Thu2Sep
Past
- Tue6Oct
Actual outcome: Bull · $2.04 at outcome
AMBR experienced a significant upward move likely driven by positive clinical trial results or regulatory progress. The move suggests strong data from a pivotal trial or a favorable FDA update, which would enhance the company's valuation and investor sentiment in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +15.8% from 2026-10-06 to 2026-10-07 (~2.4σ vs typical 1d vol). Target evaluation date 2026-10-08 (not yet reached as of 2026-10-07). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-10-08: +15.8% from 2026-10-06 (~2.4σ). Target date 2026-10-08 reached; move through 2026-10-08 observed.
AMBR experienced a significant upward move likely driven by positive clinical trial results or regulatory progress. The move suggests strong data from a pivotal trial or a favorable FDA update, which would enhance the company's valuation and investor sentiment in the ultra-short term. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +15.8% from 2026-10-06 to 2026-10-07 (~2.4σ vs typical 1d vol). Target evaluation date 2026-10-08 (not yet reached as of 2026-10-07). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-10-08: +15.8% from 2026-10-06 (~2.4σ). Target date 2026-10-08 reached; move through 2026-10-08 observed.
- Thu3Sep
Actual outcome: Bear
Amber International met EPS estimates and reported Q2 revenue of $13.9 million, up 38.8% quarter-over-quarter, driven by its strategic pivot toward specialized AI agents. While the positive sequential growth and improved gross margins sparked a modest 4% gain following the release, the stock remained well below the $1.30 bear floor, indicating that the market remains cautious about the company's long-term transition and overall valuation.
Q2 2026 results will show whether Amber can stabilize revenue after the sharp YoY decline and March loss, and whether management still guides to profitable project execution for the rest of FY26. A clean print with evidence that the March quarter was a one-off and that cash burn is under control would justify a move toward $1.70, while further margin pressure or weaker presales could pull the stock back toward $1.70.
- Mon1Jun
Actual outcome: Bear · $1.49 at outcome
Amber International's stock fell below the $1.55 bear floor after its Q1 2026 financial results highlighted a 'softer macro environment' impacting operations. Despite strategic efforts to bolster investor confidence—including a pro rata distribution to showcase its institutional shareholder base and the appointment of a sovereign wealth fund executive to the board—the company's thin balance sheet and broader macroeconomic headwinds ultimately drove a material sell-off.
Into mid-2026, Amber International trades at $2.12 with high sensitivity to President Trump’s real estate, infrastructure, and trade stance. Any mix of permitting reform or construction support versus tariff escalation on building inputs and cross-border capital flows can re-rate this $2.12 stock, as the balance sheet is thin and recent revenue growth is volatile.
